Market View

The U.S. market remains in a Confirmed Uptrend. Indices closed lower this week, with the S&P 500 and the Nasdaq declining
0.5% and 1.1%, respectively. However, indices staged an upside reversal on Friday to close back above their 21-DMA (5,243/16592)
support after briefly trading below. Distribution days have clustered a bit with three and four, respectively over three weeks.

O’Neil Health Care Weekly

XLV declined 1.3% last week and is now sitting just above 21-DMA ($144) support with the next level at the rising 50-DMA ($143). The range of resistance is between $147 to $148.27 (all-time high). Its RS line (vs. the S&P 500 and Nasdaq) is near lows, still warranting an underweight sector positioning. XLV has now been underperforming the broader market for 18 straight months.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 was flat for the week while the Nasdaq rallied ~1.3%
higher led by the technology sector. Both indices remain at or near all-time highs with the 10-DMA (5,276/16,690) as the first
level of support. The distribution day count stands at two on each index.

O’Neil Health Care Weekly

XLV rallied nearly 2% for a second straight week and is now set to test new-high resistance between $147.70 to $148.27. The 21-DMA and 50-DMA are coinciding at $143 to act as downside support. Its RS line (vs. the S&P 500 and Nasdaq) continues to trade near lows, still warranting an underweight sector positioning.

O’Neil Health Care Weekly

XLV rallied nearly 2% last week, narrowly regaining its 50-DMA ($143.18) Friday which will now act as near-term support before the rising 21-DMA ($141.61). Resistance levels are $144.52, followed by $147.70. Its RS line (vs. the S&P 500 and Nasdaq) is consolidating near lows, still warranting an underweight sector positioning.

Market View

The U.S. market remains in a Rally Attempt. The S&P 500 and Nasdaq have regained and are consolidating above 50-DMA
support (5,139/16,085). In addition, both indices are only 1% off all-time highs ( 5,264/16,538). We will shift the market status to a
Confirmed Uptrend either on a follow-through day (+1.7% on volume higher d/d) or on a close at a new all-time high.

O’Neil Health Care Weekly

XLV gained 62 bps last week, trading relatively flat for the third consecutive week and directly at its 21-DMA ($141). Resistance
remains the 100-DMA ($141.70), followed by the rolling 50-DMA ($143.43). Support is at its 200-DMA ($136). Its RS line (vs. the S&P
500 and Nasdaq) continues to trade near lows warranting an underweight sector positioning.

Market View

The U.S. market remains in a Rally Attempt. On Friday, the Nasdaq narrowly missed a day-10 follow-through day, rising 2.0% on volume that was slightly below the prior day. The S&P 500 did also rose 1.3% on Friday on lower volume. For the week, indices were up 0.5% and 1.4%, respectively. The S&P 500 is testing its 50-DMA (5,130) after trading below for three weeks. The Nasdaq retook the 50-DMA (16,058) and is back to within 2% of all-time highs after trading as much as 8% off highs.

O’Neil Health Care Weekly

XLV traded relatively flat for a second straight week, still finding resistance at its 21- and 100-DMA ($141.19), as 200-DMA ($136.10)
support steadily rises. Its RS line (vs. the S&P 500 and Nasdaq) remains in a downtrend, still warranting an underweight sector
positioning.